NCT01042964View on ClinicalTrials.gov

Safety, Pharmacokinetic and -Dynamic Study of PR-15, an Inhibitor of Platelet Adhesion

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

January 31, 2007

Study Completion Date

October 31, 2007

Conditions
ThrombosisAcute Coronary SyndromeMyocardial InfarctionStroke
Interventions
DRUG

revacept (PR-15)

single intravenous administration of revacept (PR-15), an inhibitor of platelet adhesion, in various strengths (10, 20, 40, 80, 160 mg) in healthy male volunteers.

Trial Locations (1)

02826

ABX-CRO/Medifacts GmbH, Görlitz

All Listed Sponsors
collaborator

Procorde GmbH

UNKNOWN

lead

AdvanceCor GmbH

INDUSTRY

NCT01042964 - Safety, Pharmacokinetic and -Dynamic Study of PR-15, an Inhibitor of Platelet Adhesion | Biotech Hunter | Biotech Hunter